**Methods for Treating Hemostatic Disorders by Modulating P-Selectin Activity (Anti-Thrombotic)**

**Application:** Treatment & prevention of thrombotic disorders including atherosclerosis, deep vein thrombosis, angina & restenosis following medical intervention.

**Inventors:** Denisa Wagner, Ph.D., Patrick Andre, Ph.D., Daqing Hartwell, Ph.D., Ingrid Hrachovinova, Ph.D.

**Invention Summary:**
P-selectin, a member of the selectin family, is found on the surface of platelets and endothelial cells. A soluble form of P-selectin (sP-selectin) is found in blood plasma as a protein on circulating microparticles. However, the biological role of sP-selectin and other soluble adhesion molecules circulating in the blood has not been known. Previous work by Dr. Wagner et al. has shown that P-selectin could play a role in hemostasis. Wild type mice infused with a P-selectin immunoglobulin fusion protein (P-selectin-Ig) produced a procoagulant state, which accelerated hemostasis. Studies showed that, in human blood, P-selectin-Ig induced formation of procoagulant microparticles upon binding to the P-selectin glycoprotein ligand-1 (PSGL-1). Therefore, sP-selectin plasma levels may be used to assess risk of a clotting incident. Human therapeutic methods are based on reducing hemostasis by administering an inhibitor of P-selectin activity causing a decrease in the pro-coagulant state of an individual.

**Publications:**
- *Journal of the American Heart Association*, Circulation 2001; 103; 491-495

**Supporting Publications:**

**Patent Status:**
US Issued Patent # 7,387,777
Foreign Issued Patent # 1289552 for United Kingdom, France, Germany, and Italy
US Application # 09/860,618, Publication # 20020031508
US Application # 10/999,477; US Application # 12/030,576
PCT Application # PCT/US01/16021, Publication # WO 01/89564

**Availability:** Exclusive worldwide license

**Contact:**
Ryan Dietz
Director, Office of Technology Development
617.919.3048
dietz@idi.harvard.edu